AbsTrACT background To quantitatively assess outer retinal layers in eyes with hydroxychloroquine (HCQ) toxicity.
AbsTrACT background To quantitatively assess outer retinal layers in eyes with hydroxychloroquine (HCQ) toxicity. Methods A retrospective case-control study was performed to identify eyes with HCQ retinopathy/ toxicity at Cleveland Clinic. A clinical diagnosis of HCQ retinopathy was made based on clinical and imaging features including the presence of parafoveal ellipsoid zone (EZ) loss on spectral-domain optical coherence tomography (OCT) and visual field defects. All participants underwent macular cube scan using the Cirrus HD-OCT (Zeiss, Oberkochen, Germany). Quantitative assessment of outer nuclear layer (ONL)/ Henle fibre layer complex (HFL) metrics and EZ mapping were performed with a novel software platform and compared with age-matched controls. HCQ toxicity group was divided into three subgroups based on the severity. results There were 14 eyes from 14 patients in HCQ toxicity group (mean age 57.0±18.6 years), and 14 eyes from 14 subjects in age-matched control group (mean age 59.4±18.6 years). Multiple outer retinal parameters including ONL/HFL-EZ volume, parafoveal ONL/HFL-EZ thickness and EZ-retinal pigment epithelium (RPE) volume were significantly reduced in all HCQ toxicity subgroups (early, moderate and advanced toxicity) compared with controls. Semiautomated layer segmentation tool produced en face representation of EZ-RPE mapping and allowed unique visualisation of EZ attenuation in eyes with HCQ toxicity. The longitudinal analysis of HCQ toxicity group demonstrated progressive decline in some outer retinal parameters. Conclusion HCQ toxicity resulted in significant outer retinal layer volumetric thinning compared with controls. Quantitative assessment of outer retinal parameters and EZ mapping on SD-OCT may become a useful biomarker to identify and monitor HCQ toxicity.
InTroduCTIon
Hydroxychloroquine (HCQ; Plaquenil) retinopathy (ie, HCQ toxicity) is a severe complication associated with HCQ intake that can cause irreversible vision loss. [1] [2] [3] Early detection of retinal toxicity is crucial since vision loss is usually permanent and cellular damage may progress despite discontinuation of treatment. 2 3 Although no ideal single test exists for identification of early toxicity, spectral-domain optical coherence tomography (SD-OCT) plays a critical role in identifying photoreceptor and retinal pigment epithelium (RPE) involvement that can be used for both screening and monitoring purposes. 2 4-6 To date, several investigators have used SD-OCT in eyes with HCQ toxicity and qualitatively evaluated thinning of the outer retinal layers or attenuation of the ellipsoid zone (EZ), while others have quantitatively analysed outer retinal thickness on SD-OCT topographic map. [7] [8] [9] [10] This study aims to characterise HCQ toxicity using a newly developed assessment tool for retinal layer segmentation and mapping on SD-OCT. 11 
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MeThods
This study was an institutional review board-approved retrospective case-control series. A medical records search was performed to identify subjects with HCQ toxicity based on clinical (eg, visual field defects) and imaging features (eg, parafoveal EZ loss). Macular cube scan was obtained using Cirrus HD-OCT (Zeiss, Oberkochen, Germany) with a raster scan pattern 512×128 A-scans covering a 6×6 mm area centred on the fovea. SD-OCT data were imported into a semiautomated layer segmentation tool for outer retinal mapping. 11 12 The software provides automated segmentation of the internal limiting membrane, outer boundaries of the outer plexiform layer (ONL), EZ band and RPE as shown in figure 1 . The generated segmentation lines were carefully reviewed by an image analyst, and segmentation errors were manually corrected. En face EZ topographic maps were generated to visualise overall EZ alterations, the severity of loss and regional location.
Data containing various outer retinal parameters as listed in table 1 were subsequently exported and evaluated: 'central subfield' and 'parafoveal' were defined as a distance of 0.5 and 1.0 mm from the fovea, respectively. ONL/Henle fibre layer complex (ONL/HFL)-EZ represented the gap between inner boundaries of ONL/HFL to EZ band whereas EZ-RPE represented the gap between photoreceptor EZ band to RPE mitochondria zone. 13 The en face EZ-RPE topographic map provided calculations related to the percentage of total EZ attenuation (ie, the measurement value of EZ-RPE thickness of 0 µm) and partial EZ attenuation (EZ-RPE thickness <10 and <20 µm). Outer retinal parameters were compared between eyes with HCQ toxicity and controls. The longitudinal assessment of outer retinal parameters in HCQ toxicity group was completed to evaluate outer retinal change over time with a follow-up visit of more than 6 months. Baseline was defined as the time of diagnosis or suspected HCQ toxicity. The right eye for each subject was used for analysis. Data are presented as mean±SD. All p values were two-tailed, and p<0.05 was considered statistically significant.
resulTs
Overall, 14 right eyes from 14 patients were included in both HCQ toxicity group and the age-matched control group (baseline characteristics of patients are presented in online supplementary table 1). In HCQ toxicity group, the mean age at presentation was 57.0±18.6 years (range 17-90), the mean duration of drug exposure was 20.6±15.0 years (range 2-45) and the mean daily dosing based on actual body weight (ABW) was 5.5±1.6 mg/ kg/day (range 3.4-8.6). Clinical severity of HCQ retinopathy based on Marmor's grading scale at baseline visit was early disease in five eyes, moderate in six eyes and advanced in three eyes, respectively.
14 The patient with the lowest dosing in each Figure 3 displays a representative case with HCQ toxicity of longitudinal progression.
Innovations
dIsCussIon
In this report, a semiautomated layer segmentation tool successfully allowed quantitative assessment of outer retinal thickness/ volume, percentage of EZ-RPE attenuation/loss and produced en face representation of EZ-RPE mapping. It also allowed unique visualisation of EZ attenuation in subjects with HCQ toxicity. In HCQ toxicity group, multiple outer retinal parameters were significantly reduced possibly indicating a loss of photoreceptors and RPE cells. Our study was in reasonable agreement with previous studies that demonstrated the progression of outer retinal thinning. 8 15 Meanwhile, the foveal EZ-RPE thickness showed a significant increase. It has been recently reported that HCQ suppresses the activity of an organic anion transporting polypeptide 1A2 (OATP1A2) expressed in the RPE, which mediates the uptake of all-trans-retinol, an essential process in the retinoid visual cycle. 16 It is possible that the increased EZ-RPE thickness at follow-up visit might be due to the functional recovery of remaining photoreceptors with elongation of the outer segment following cessation of HCQ intake. Quantification of outer retinal changes in patients undergoing HCQ therapy may allow efficient assessment for the progression of HCQ toxicity. This technology may provide an additional tool for toxicity screening in the future, but more research is needed.
Our study is limited by retrospective nature of the study and small sample size with variable follow-up periods. Wide-field 9×9 mm volume scans may better allow the identification of pericentral photoreceptor changes in certain ethnic groups (eg, Asians). 6 Also, in eyes with tilted OCT images, retinal thickness measurements may be exaggerated with broadened scan area coverage since the thickness was measured parallel to the vertical axis of the B-scans. 17 18 The development of mathematical adjustment may be warranted. Moreover, due to the optical properties of HFL, it is possible that eyes with OCT image tilt may have resulted in less consistent measurements in the ONL/ HFL boundary. 17 In conclusion, this study provides evidence of the potential value of quantitative outer retinal parameters and en face EZ-RPE mapping on SD-OCT as a quantitative biomarker in a clinical setting to diagnose and monitor HCQ toxicity.
